STAT62%
FDA expert committee votes in favor of Replimune’s melanoma treatment 55%
By Matthew Herper94% Elaine Chen61%
7/30/2026, 3:00:00 AM
BS Summary: This article contains 17 faulty reasoning types, including Post Hoc (False Cause), Framing Effect, and Recency Bias, with Biased Writer Voice as the most egregious example at 37.3% saturation with 56 hits. Analysis detected 429 faulty-reasoning hits from 150 analyzed words, generating a BS Score of 45% and a BS Rank of 55% (13,847 of 30,584 articles). This article is worse (more manipulative) than 54.70% of the article peer group.
A group of outside experts convened by the Food and Drug Administration on Thursday voted in favor of Replimune’s experimental treatment for advanced melanoma.
In a 10-3 vote, the advisers determined that the biotech company has collected sufficient data to allow the FDA to review RP1, an engineered viral immunotherapy for melanoma.
The agency tends to follow the recommendations of its expert panels but is not bound by them.
What comes next could be seen by some as a signal of how the FDA, under new leadership, weighs potential benefits and risks when it comes to investigational drugs.
RP1 was initially rejected last year, under former FDA leaders Marty Makary and Vinay Prasad.
But STAT reported that earlier resistance to RP1 was based on the views of former top oncology regulator Rick Pazdur.
The drug was again rejected this April.
Speakers
Loading…
Loading…
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.